5 Best Day Trading Stocks to Buy Now

2. Mineralys Therapeutics Inc. (NASDAQ:MLYS)

Number of Hedge Fund Holdings: 88

Biopharmaceutical company Mineralys Therapeutics Inc. (NASDAQ:MLYS) scored a win on March 9th when it announced that the Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for its lorundrostat drug to treat hypertension when combined with other hypertensive drugs. As part of the release, the firm’s CEO outlined that while the drug’s Explore-OSA trial did not show a reduction in the apnea-hypopnea index (AHI), the drug’s safety profile and its impact on blood pressure were nevertheless meaningful.

The FDA’s NDA approval came after Mineralys Therapeutics Inc. (NASDAQ:MLYS) announced in January that it had submitted the application. In December 2025, Bank of America raised the firm’s share price target to $46 from $43 and kept a Buy rating on the stock. The coverage came after Mineralys Therapeutics Inc. (NASDAQ:MLYS)’s earnings report for the third quarter of 2025, which saw the firm confirm that it had a cash runway up to 2027.

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is a biotechnology company that is focused on developing drugs for ailments stemming from aldosterone dysregulation. It is headquartered in Radnor, Pennsylvania.